Questions to Ask Your Doctor About HRT

The short version

The question that changes an HRT decision is not "is HRT safe?" — that question has no useful answer. It is seven specific ones: Am I a candidate? Which type and which route? What are my risks in absolute numbers? What should I expect, and when? How will we follow up, and for how long? What about vaginal symptoms specifically? And what will this cost me?

A good consultation is one where your clinician can answer all seven with reference to your history — your age, your years since your last period, your clotting history, whether you still have a uterus. A clinician who says HRT is "too risky" without ever discussing your individual risk has not given you enough information to make a decision. Neither has one who hands you a script in four minutes without asking about your uterus.

Print this, or take the output of our menopause doctor report with you. Ten to fifteen minutes goes very fast.

Before you go: four facts to have written down

Most of the questions below only work if you can answer these first. Put them at the top of the page:

• The date of your last period (or your best estimate), and your age now.
• Whether you still have a uterus — and if you have had surgery, whether the ovaries came out too. This single fact decides half the prescription.
• Your clot and stroke history, and your family's — any DVT, pulmonary embolism, stroke or heart attack in you or a first-degree relative, and whether it was provoked (surgery, pregnancy, a long flight) or came out of nowhere.
• Your top three symptoms, ranked, and what they are costing you. "I wake four times a night and I've stopped driving to work" lands very differently from "I've been a bit tired."

Set 1: Am I a candidate — and what would rule me out?

Ask: "Given my history, is there anything that makes systemic HRT a bad idea for me?" Then, specifically: "Do I have any of the absolute contraindications?"

Why it matters: most of what women are told disqualifies them — high blood pressure, a family history of breast cancer, being "too old at 54" — does not. The list of things that genuinely change the conversation is short:

• Unexplained vaginal bleeding. Bleeding after menopause has to be investigated before hormones enter the picture, because starting HRT muddies the picture and delays the workup. See postmenopausal bleeding.
• A hormone-sensitive cancer (breast, endometrial), current or past. This is an oncology conversation, not a routine one.
• A prior venous thromboembolism (VTE), stroke, or heart attack. Not always an absolute no — route matters here, see Set 2 — but it has to be discussed explicitly, not glossed over.
• Active liver disease.
• A known clotting disorder (Factor V Leiden, for example), or a first-degree relative with an unprovoked VTE. At minimum this should change the route of delivery.

Then ask about timing. "How many years am I from my last period, and does that change the calculation?" The Menopause Society's position is that for women under 60, or within about 10 years of the onset of menopause, with no contraindications, the benefit-to-risk ratio is favourable for treating bothersome hot flashes and night sweats. Start more than 10 years out, or past 60, and the ratio becomes less favourable — largely because the underlying absolute risks of coronary disease, stroke, VTE and dementia are higher at that age, so the same relative effect produces more actual events. That is the "timing hypothesis," and it is the single most useful frame in the room.

What a good answer sounds like: "You're 51, three years since your last period, no clot history, no bleeding — you're squarely in the window where the evidence is most favourable. What I want to check is your blood pressure and your family clot history."

Set 2: Which type and which route — and why?

These are two separate questions, and both get skipped.

"Do I need a progestogen, and what is protecting my uterus?"

If you have a uterus and you take systemic estrogen without adequate progestogen, the endometrial lining is stimulated unopposed — and that raises the risk of endometrial hyperplasia and endometrial cancer. This is the one boxed warning the FDA kept when it overhauled menopausal hormone labelling in November 2025: systemic estrogen-alone products still carry an endometrial cancer boxed warning, even as the warnings on cardiovascular disease, breast cancer and probable dementia came off.

So ask it out loud: "I have a uterus. What is protecting my endometrium, and is the dose and schedule adequate?" A progestogen-releasing IUD, oral micronised progesterone, or a combined patch are all legitimate answers. "You'll be fine" is not. If you have had a hysterectomy, estrogen alone is standard and no progestogen is needed for endometrial protection. More detail: estrogen-only vs combined HRT.

"Patch, gel, spray or pill — and why that one for me?"

Oral estrogen passes through the liver first (first-pass metabolism), where it shifts the production of clotting proteins. Transdermal estrogen — patch, gel, spray — largely bypasses that. A systematic review and meta-analysis in the Journal of Clinical Endocrinology & Metabolism (2015) pooled 15 observational studies and found that, compared with transdermal estrogen, oral estrogen was associated with a higher risk of a first VTE (risk ratio 1.63, 95% CI 1.40–1.90) and of deep vein thrombosis. The authors rated confidence in that evidence as low, because it is observational rather than randomised — but it points consistently one way, and it underpins guideline advice: UK NICE guidance directs clinicians towards transdermal estrogen for women at increased risk of VTE, including those with a BMI over 30.

So if you have a raised BMI, a clot history, migraine with aura, or gallbladder disease, route is not a preference question — it is a clinical one, and you are entitled to hear the reasoning out loud. See HRT pills vs patches vs gels.

Set 3: "What are my risks in absolute numbers, not relative ones?"

This is the question that most changes what you walk out believing, and almost nobody asks it.

"A 25% increase in breast cancer risk" is a meaningless sentence on its own. Twenty-five per cent of what? If your baseline risk over a given period is 1 in 100, a 25% relative increase makes it 1.25 in 100 — a quarter of one extra case per hundred women. The number that means something is the absolute one: how many extra cases, among how many women, over how many years.

Here is the reference point to have in your head. In the Women's Health Initiative estrogen-plus-progestin trial — conjugated equine estrogen with medroxyprogesterone acetate, in women whose average age at entry was 63 — the absolute excess was about 8 additional invasive breast cancers per 10,000 women per year, over an average of roughly five years. That is about one extra case per 1,250 women per year of use. In the same programme's estrogen-alone arm — women who had had a hysterectomy — breast cancer incidence was not raised at all: it ran below placebo (hazard ratio 0.77), and in long-term follow-up that reduction reached statistical significance. Those two results come from the same trial programme and are routinely collapsed into one headline.

So ask: "Per 1,000 women like me, over five years, how many extra cases of [breast cancer / clot / stroke] would you expect — and what is the baseline without HRT?" If your clinician doesn't have the number to hand, that is fine; ask them to look it up, or to point you to where it is written down. What is not fine is being handed percentages alone.

This is also the moment to ask which population the numbers come from. Much of what women are told derives from a trial whose average participant was more than a decade past menopause and taking an oral formulation that is no longer the default first choice. The FDA's November 2025 decision to remove the boxed warnings on cardiovascular disease, breast cancer and probable dementia from estrogen-containing menopausal products turned on exactly that mismatch — see what the FDA boxed-warning removal actually changed. Removing a warning label is not the same as proving there is no risk. It means the blanket framing was judged wrong, and that the numbers now have to be individualised. In the room, that is your job as much as your clinician's.

Set 4: What should I expect, and when?

Ask: "How long before I know whether this is working?" and "What is normal in the first three months, and what isn't?"

Hot flashes and night sweats typically respond over weeks rather than days; many women notice a difference within about four to eight weeks, and it is reasonable to give a regimen around three months before judging that it has failed. Sleep and mood often track the vasomotor symptoms. Vaginal dryness treated with local estrogen usually takes longer — often 8 to 12 weeks for the full effect.

The one you must ask about specifically is bleeding. On continuous combined HRT, unpredictable spotting or light bleeding in the first three to six months is common and expected while the endometrium settles. After that window it stops being expected: new or persistent bleeding beyond roughly six months, or bleeding that starts up again after a settled bleed-free stretch, needs assessment. Get your clinician to state that window out loud, so you know when it is time to call rather than wait and see. See bleeding on HRT.

Ask, too, which early effects usually settle by themselves (breast tenderness, mild nausea, headache in the first weeks) and which ones mean picking up the phone rather than waiting for the review.

Set 5: "How will we follow up — and how long will I be on this?"

Ask: "When do we review? What would make us change the dose or the route? And is there a point at which you would want me to come off it?"

There is no arbitrary stop date. The old rule of thumb — five years and out, or stop at 60 — is not what the guidelines say. The Menopause Society's position is that duration should be individualised and reviewed periodically, with no blanket requirement to discontinue at a given age or after a given number of years, provided the benefits still outweigh the risks for you and that judgement is actually being revisited. Some women stay on treatment for many years; some come off when symptoms settle. Both are legitimate, and neither should be decided by a calendar alone.

What you want out of this exchange is a named review point — a first check at around three months is common, then at least annually — and a shared understanding of what "still working" would look like.

Set 6: What about vaginal symptoms specifically?

Ask this even if you are not planning to take systemic HRT: "Is low-dose vaginal estrogen a separate decision?"

It is. Local vaginal estrogen — cream, tablet, ring — is absorbed into the bloodstream in only minimal amounts, which is why it does not carry the same systemic risk profile, and why the FDA's 2025 labelling changes removed the boxed warning from low-dose vaginal products altogether. It treats dryness, painful sex, and the urinary symptoms of genitourinary syndrome of menopause. It can be used alongside systemic HRT or entirely on its own, and it is often an option for women who cannot take systemic hormones — worth asking about explicitly if that is you.

Two things make it worth its own question. Unlike hot flashes, these symptoms do not fade with time: left untreated, they tend to progress. And systemic HRT at a standard dose does not always fully resolve them, so "I'm already on a patch" is not a reason to skip the conversation. More: vaginal estrogen.

Set 7: Cost and coverage

Ask before you leave the room: "Is this covered by my plan? Is there a generic? Will it need prior authorisation?" Patches, gels and micronised progesterone vary considerably in price, and the gap between a covered generic and a brand can be substantial month to month — which matters, because the treatment that works is the one you can afford to keep collecting. If you are told a product needs prior authorisation, ask what documentation the office will submit, and when. Our cost and coverage estimator and what HRT actually costs are more useful before the appointment than after it.

One more question, if HRT turns out not to be an option for you: "What non-hormonal treatments would you consider, and how well do they actually work?" There are prescription non-hormonal options for hot flashes — including the neurokinin-receptor antagonist fezolinetant, FDA-approved in 2023, whose label requires liver blood-test monitoring — plus certain antidepressants, and cognitive behavioural therapy, which has evidence for reducing how much hot flashes bother you even where it does not abolish them. Ask what applies to you, rather than assuming HRT is the only door.

Red flags in the answer

Two answers should make you consider a second opinion.

"HRT is too risky." Full stop, with no discussion of your age, your years since menopause, your clot history, or the route. That is a clinician working from a 2002 headline. The evidence has moved, and so has the regulator. You are entitled to a conversation about your risk, not a category refusal.

A service selling compounded hormone pellets. Compounded "bioidentical" hormone preparations are not FDA-approved products. The 2020 National Academies review, commissioned by the FDA, found the evidence base for compounded bioidentical hormone therapy to be poor — leaning on anecdote, patient report and prescriber testimony rather than controlled trials — and recommended restricting its use. Pellets are a particular problem: once implanted, the dose cannot be dialled down or taken back out, and adverse-event reports associated with compounded pellets have included abnormal bleeding, endometrial cancer, clots and pellets working their way out through the skin. If a clinic's business model is pellets plus a supplement stack plus a saliva hormone test, that is a sales funnel, not a treatment plan. FDA-approved estradiol and micronised progesterone are themselves chemically identical to the hormones your body makes — you do not need a compounding pharmacy to get "body-identical" hormones. See bioidentical hormones.

Two softer flags: a clinician who will not tell you what is protecting your uterus, and one who will not book a follow-up.

When to see a doctor — and when to go sooner

Book an appointment to talk about HRT if hot flashes, night sweats, disrupted sleep, mood change, or vaginal and urinary symptoms are interfering with your life. You do not have to be "bad enough" to qualify: bothersome is the threshold the guidelines use.

Do not wait for a routine appointment — contact a clinician promptly if you have:

• Any vaginal bleeding after 12 months without a period, or new bleeding on HRT after a settled bleed-free stretch
• New calf pain, swelling, redness or warmth in one leg, or sudden breathlessness or chest pain — a possible clot, and an emergency
• Sudden severe headache, visual change, weakness or difficulty speaking — an emergency
• A new breast lump, skin change or nipple discharge
• Yellowing of the skin or eyes, or severe abdominal pain

Nothing here is a prescription, or advice to start, stop or change any hormone therapy — that decision belongs to you and your clinician. It is a list of the things worth making them say out loud. If you cannot get that conversation locally, finding a menopause specialist is a reasonable next move; and if you want the whole picture first, start with our guide to hormone replacement therapy, or browse everything in menopause.